- Earlier today, Merus N.V. MRUS announced the publication of the abstract highlighting interim data from the ongoing phase 1/2 trial of the bispecific antibody MCLA-129 in advanced non-small cell lung cancer (NSCLC) and other solid tumors.
- Needham says that the first clinical data readout from MCLA-129 suggests that the drug has a clinical profile comparable to Johnson & Johnson's JNJ Rybrevant (amivantamab).
- The analyst keeps the Buy rating and a price target of $45.
- Also Read: Needham Says Merus' ASCO Update On Zeno 'Positive'
- While available data are limited efficacy appears to be comparable, and MCLA-129 saw one ≥ Grade 3 infusion-related reaction, whereas the analyst had not seen any with amivantamab at the WCLC 2018 update.
- 13 patients were evaluable for response with preliminary signs of anti-tumor activity observed, including two partial responses (one confirmed) in EGFR mt NSCLC and four confirmed stable disease.
- The analyst says that while expectations for MCLA-129 have come down, with the stock down ~20% over the past month, investors were looking for a competitive clinical profile.
- Price Action: MRUS shares are up 1.71% at $19.66 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in